198 related articles for article (PubMed ID: 24786638)
1. Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.
Shah NR; Tancioni I; Ward KK; Lawson C; Chen XL; Jean C; Sulzmaier FJ; Uryu S; Miller NL; Connolly DC; Schlaepfer DD
Gynecol Oncol; 2014 Jul; 134(1):104-11. PubMed ID: 24786638
[TBL] [Abstract][Full Text] [Related]
2. FAK Inhibition disrupts a β5 integrin signaling axis controlling anchorage-independent ovarian carcinoma growth.
Tancioni I; Uryu S; Sulzmaier FJ; Shah NR; Lawson C; Miller NL; Jean C; Chen XL; Ward KK; Schlaepfer DD
Mol Cancer Ther; 2014 Aug; 13(8):2050-61. PubMed ID: 24899686
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression.
Ward KK; Tancioni I; Lawson C; Miller NL; Jean C; Chen XL; Uryu S; Kim J; Tarin D; Stupack DG; Plaxe SC; Schlaepfer DD
Clin Exp Metastasis; 2013 Jun; 30(5):579-94. PubMed ID: 23275034
[TBL] [Abstract][Full Text] [Related]
4. Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.
Shapiro IM; Kolev VN; Vidal CM; Kadariya Y; Ring JE; Wright Q; Weaver DT; Menges C; Padval M; McClatchey AI; Xu Q; Testa JR; Pachter JA
Sci Transl Med; 2014 May; 6(237):237ra68. PubMed ID: 24848258
[TBL] [Abstract][Full Text] [Related]
5. E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in Merlin-negative malignant mesothelioma cells.
Kato T; Sato T; Yokoi K; Sekido Y
Oncogene; 2017 Sep; 36(39):5522-5531. PubMed ID: 28553954
[TBL] [Abstract][Full Text] [Related]
6. Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.
Kanteti R; Mirzapoiazova T; Riehm JJ; Dhanasingh I; Mambetsariev B; Wang J; Kulkarni P; Kaushik G; Seshacharyulu P; Ponnusamy MP; Kindler HL; Nasser MW; Batra SK; Salgia R
Cancer Biol Ther; 2018 Apr; 19(4):316-327. PubMed ID: 29303405
[TBL] [Abstract][Full Text] [Related]
7. Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK.
Poulikakos PI; Xiao GH; Gallagher R; Jablonski S; Jhanwar SC; Testa JR
Oncogene; 2006 Sep; 25(44):5960-8. PubMed ID: 16652148
[TBL] [Abstract][Full Text] [Related]
8. FAK inhibitor PF-562271 inhibits the migration and proliferation of high-grade serous ovarian cancer cells through FAK and FAK mediated cell cycle arrest.
Pan Q; Wang Q; Zhao T; Zhao X; Liang Y; Shi M; Chen C; Lin F
Med Oncol; 2023 Jun; 40(8):215. PubMed ID: 37382687
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Potential of Focal Adhesion Kinase Inhibition in Small Cell Lung Cancer.
Aboubakar Nana F; Lecocq M; Ladjemi MZ; Detry B; Dupasquier S; Feron O; Massion PP; Sibille Y; Pilette C; Ocak S
Mol Cancer Ther; 2019 Jan; 18(1):17-27. PubMed ID: 30352800
[TBL] [Abstract][Full Text] [Related]
10. FAK activity protects nucleostemin in facilitating breast cancer spheroid and tumor growth.
Tancioni I; Miller NL; Uryu S; Lawson C; Jean C; Chen XL; Kleinschmidt EG; Schlaepfer DD
Breast Cancer Res; 2015 Mar; 17():47. PubMed ID: 25880415
[TBL] [Abstract][Full Text] [Related]
11. Targeting glutamine metabolism and the focal adhesion kinase additively inhibits the mammalian target of the rapamycin pathway in spheroid cancer stem-like properties of ovarian clear cell carcinoma in vitro.
Sato M; Kawana K; Adachi K; Fujimoto A; Yoshida M; Nakamura H; Nishida H; Inoue T; Taguchi A; Ogishima J; Eguchi S; Yamashita A; Tomio K; Wada-Hiraike O; Oda K; Nagamatsu T; Osuga Y; Fujii T
Int J Oncol; 2017 Apr; 50(4):1431-1438. PubMed ID: 28259988
[TBL] [Abstract][Full Text] [Related]
12. Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer.
Kang Y; Hu W; Ivan C; Dalton HJ; Miyake T; Pecot CV; Zand B; Liu T; Huang J; Jennings NB; Rupaimoole R; Taylor M; Pradeep S; Wu SY; Lu C; Wen Y; Huang J; Liu J; Sood AK
J Natl Cancer Inst; 2013 Oct; 105(19):1485-95. PubMed ID: 24062525
[TBL] [Abstract][Full Text] [Related]
13. Frequent Loss of NISCH Promotes Tumor Proliferation and Invasion in Ovarian Cancer via Inhibiting the FAK Signal Pathway.
Li J; He X; Dong R; Wang Y; Yu J; Qiu H
Mol Cancer Ther; 2015 May; 14(5):1202-12. PubMed ID: 25724667
[TBL] [Abstract][Full Text] [Related]
14. A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors.
Soria JC; Gan HK; Blagden SP; Plummer R; Arkenau HT; Ranson M; Evans TR; Zalcman G; Bahleda R; Hollebecque A; Lemech C; Dean E; Brown J; Gibson D; Peddareddigari V; Murray S; Nebot N; Mazumdar J; Swartz L; Auger KR; Fleming RA; Singh R; Millward M
Ann Oncol; 2016 Dec; 27(12):2268-2274. PubMed ID: 27733373
[TBL] [Abstract][Full Text] [Related]
15. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
[TBL] [Abstract][Full Text] [Related]
16. The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours.
Ammoun S; Schmid MC; Zhou L; Hilton DA; Barczyk M; Hanemann CO
Mol Oncol; 2015 Jan; 9(1):236-48. PubMed ID: 25217104
[TBL] [Abstract][Full Text] [Related]
17. Targeted inhibition of FAK, PYK2 and BCL-XL synergistically enhances apoptosis in ovarian clear cell carcinoma cell lines.
Yoon H; Choi YL; Song JY; Do I; Kang SY; Ko YH; Song S; Kim BG
PLoS One; 2014; 9(2):e88587. PubMed ID: 24523919
[TBL] [Abstract][Full Text] [Related]
18. Oxidative stress-induced FAK activation contributes to uterine serous carcinoma aggressiveness.
Lopez-Mejia IC; Pijuan J; Navaridas R; Santacana M; Gatius S; Velasco A; Castellà G; Panosa A; Cabiscol E; Pinyol M; Coll L; Bonifaci N; Peña LP; Vidal A; Villanueva A; Gari E; Llobet-Navàs D; Fajas L; Matias-Guiu X; Yeramian A
Mol Oncol; 2023 Jan; 17(1):98-118. PubMed ID: 36409196
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of 7-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-2,3-dihydro-1H-inden-1-one derivatives as potent FAK inhibitors for the treatment of ovarian cancer.
Wei W; Feng Z; Liu Z; Li X; He H; Ran K; Shi Y; Zhu Y; Ye T; Gao C; Wang N; Yu L
Eur J Med Chem; 2022 Jan; 228():113978. PubMed ID: 34810020
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of the NF2 tumor suppressor protein merlin in DU145 prostate cancer cells.
Horiguchi A; Zheng R; Shen R; Nanus DM
Prostate; 2008 Jun; 68(9):975-84. PubMed ID: 18361411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
